intracellular infection

Methicillin sodium salt (Meticillin sodium) is a β-lactam antibiotic (natural product), a penicillin-binding protein inhibitor (anti-Staphylococcus aureus MIC=2.1 μg/mL), used for research on Staphylococcus aureus infections and inflammation-related studies.

Anti-PEDV agent 1 (Compound D39) is a potent inhibitor of porcine epidemic diarrhea virus (PEDV) with an EC50 value of 0.09 μM. By modulating intracellular Ca2+ homeostasis, it obstructs the early internalization of PEDV during the viral entry stage. Anti-PEDV agent 1 shows promise for use in PEDV infection research.

Antituberculosis agent-15 (Compound 18c) is a selective antimycobacterial agent with a minimum inhibitory concentration (MIC) of 0.45 μM against Mycobacterium tuberculosis H37Rv (ATCC 27294) and 0.28 μM against its wild-type strain H37Rv-LP (ATCC 25618). It exhibits potent intracellular inhibitory activity in macrophage infection models, with an IC50 of 0.16 μM. Antituberculosis agent-15 is applicable for tuberculosis research.

TH16 is an antimicrobial agent with a minimum inhibitory concentration (MIC) of 2 μg/mL against methicillin-resistant Staphylococcus aureus (MRSA). It disrupts the integrity of the bacterial cytoplasmic membrane, leading to an increase in intracellular reactive oxygen species (ROS) levels, ultimately causing bacterial death. TH16 holds potential for research in bacterial infection.

VKT-17-P4-23 is a blood-brain barrier-permeable DksA inhibitor targeting the highly conserved transcriptional regulator DksA in Gram-negative bacteria, with a Kd value of 124 μM. Through modulation of the DksA-regulated SPI-2-dependent survival pathway, VKT-17-P4-23 exhibits antibacterial activity against planktonic and intracellular pathogens including Salmonella and additionally demonstrates activity against persistent bacterial populations that are difficult to eradicate. VKT-17-P4-23 is applicable to investigations involving Salmonella infection, bacterial persistence mechanisms, and transcriptional regulation in pathogenic bacteria.

Debio 1453 is a potent bactericidal FabI inhibitor that is effective against Neisseria gonorrhoeae (IC50 = 0.6 nM) as well as its resistant strains. By inhibiting FabI and binding the non-mutatable NADH cofactor, Debio 1453 demonstrates a low propensity for resistance selection and effectively targets both planktonic and intracellular bacteria. It is capable of eradicating resistant Neisseria gonorrhoeae infections in a mouse vaginal infection model. Debio 1453 can be utilized in gonorrhea-related research.

K6PC-5 is a ceramide derivative that acts as an activator of sphingosine kinase 1 (SPHK1), inducing a swift and temporary rise in intracellular calcium levels. With its potential applications in skin diseases associated with abnormal keratinocyte function, as well as in studies on neurodegeneration and virus infection, K6PC-5 presents a promising compound for research purposes.

S-Acetyl-L-glutathione is a derivative of glutathione .1 It increases intracellular GSH levels in primary fibroblasts derived from patients with glutathione synthetase deficiency when used at a concentration of 50 μM. S-Acetyl-L-glutathione (5 mM) induces apoptosis in Daudi, Raji, and Jurkat lymphoma cells.2 It inhibits the replication of herpes simplex virus 1 (HSV-1) in human foreskin fibroblasts when used at concentrations of 5 and 10 mM.3 S-Acetyl-L-glutathione (6.25 μg/g per day) increases survival in a mouse model of HSV-1 infection.

GSK812397 is a potent entry inhibitor of X4-tropic strains of HIV-1, as demonstrated in multiple in vitro cellular assays. GSK812397 is a noncompetitive antagonist of the CXCR4 receptor, with GSK812397 producing a concentration-dependent decrease in both an SDF-1-mediated chemotaxis and intracellular calcium release (IC50s were 0.34+/-0.01 nM and 2.41+/-0.50 nM, respectively). GSK812397 is effective against a broad range of X4- and X4R5-utilizing clinical isolates. The potency and efficacy of GSK812397 are dependent on the individual isolate, with complete inhibition of infection observed with 24 of 30 isolates. GSK812397 does not show any detectable in vitro cytotoxicity and was highly selective for CXCR4. GSK812397 shows acceptable pharmacokinetic properties and bioavailability across species. GSK812397 has antiviral activity against a broad range of X4-utilizing strains of HIV-1 via a noncompetitive antagonism of the CXCR4 receptor.

1. Farrerol has antioxidative activity.2. Farrerol modulates TAP and BNBD5 gene expression in mammary gland, enhances bMEC defense against S. aureus infection and could be useful in protection against bovine mastitis. 3. Farrerol inactivates KEAP-1 or act

ent-Abacavir is an enatiomer of Abacavir. Abacavir is a carbocyclic 2'-deoxyguanosine nucleoside reverse transcriptase inhibitor and an anti-HIV drug used to treat HIV infection. Intracellular enzymes convert Abacavir to its active form, carbovir-triphosphate (CBV-TP), which then selectively inhibits HIV reverse transcriptase by incorporating into viral DNA. Abacavir is metabolized in the liver by uridine diphosphate glucuronyltransferase and alcohol dehydrogenase resulting in inactive glucuronide and carboxylate metabolites, respectively.

S)-(-)-Perillic acid is a terpenoid natural product capable of inhibiting protein pentosylisation and protein acylation. It exhibits anti-infective and anti-cancer activity, inducing cell cycle arrest and apoptosis in non-small cell lung cancer cells while increasing intracellular protein levels of Bax, p21, and caspase-3.

Ansuvimab is a humanizing neutralizing monoclonal antibody targeting the glycoprotein (GP) of Zaire ebolavirus (EBOV). The antibody specifically binds to a highly conserved epitope (LEIKKPDGS) within the receptor-binding site of the EBOV GP1 subunit, effectively blocking the interaction between the viral glycoprotein and the host intracellular Niemann-Pick C1 (NPC1) receptor. In addition to its neutralizing activity, Ansuvimab mediates antibody-dependent cellular cytotoxicity (ADCC) to facilitate the clearance of infected cells by the immune system. As the first approved treatment for Ebola virus infection, it possesses significant clinical value in reducing viral load and improving patient survival rates.

Influenza NP (311-325) is a biologically active peptide consisting of amino acids 311 to 325 from the influenza virus nucleoprotein (NP). As a bona fide MHC class II-restricted epitope, it is critical for studying host immune responses during viral infection, inducing robust gamma interferon (IFN-gamma) production in intracellular cytokine assays without stimulating CD8 T-cells in mice. The presence of Glutamine (Q) or Glutamic acid (E) at the N-terminus can lead to spontaneous formation of Pyroglutamyl (pGlu) peptides, enhancing peptide stability against gastrointestinal proteases. These peptides are considered a normal variant and included in peptide purity measurements in HPLC analysis.

Farrerol (Standard) is a reference standard for research and analysis in studies involving Farrerol. 1. Farrerol has antioxidative activity.2. Farrerol modulates TAP and BNBD5 gene expression in mammary gland, enhances bMEC defense against S. aureus infection and could be useful in protection against bovine mastitis. 3. Farrerol inactivates KEAP-1 or activates the Akt, p38 and ERK to facilitate the release of Nrf2 from Keap1 and subsequent reduces the intracellular production of reactive oxygen species via the induction of HO-1 expression. 4. Farrerol has protective effects against H2O2-induced apoptosis in EA.hy926 cells, and suggests that Farrerol is a potential candidate for the intervention of endothelial-injury-associated cardiovascular diseases.